Liminal BioSciences is a biotechnology company that specializes in developing small molecule compounds for respiratory, liver, and renal diseases. It focuses on providing solutions for rare and orphan disorders. The company is engaged in the development of PBI-4050, an anti-inflammatory and anti-fibrotic agent with the potential to treat Alström syndrome (ALMS), idiopathic pulmonary fibrosis (IPF), and scleroderma.